Department of Endocrinology and Nutrition, Hospital General Universitario de Castellón, Avinguda de Benicàssim, 128, 12004, Castelló de la Plana, Castelló, Spain.
Departament of Medicine, Jaume I University, Castelló de la Plana, Castelló, Spain.
J Endocrinol Invest. 2022 May;45(5):1071-1077. doi: 10.1007/s40618-022-01739-0. Epub 2022 Jan 11.
To describe a case series of thyrotoxicosis likely triggered by SARS-CoV-2 vaccination and to warn physicians about this potential correlation. To report clinical, laboratory and imaging findings and provide further information that goes in line with the underlying mechanisms.
Single-center case series based on all the information collected in the hospital medical records, as well as the temporal sequence between the onset of symptoms and COVID-19 vaccination.
We report 8 cases with thyrotoxicosis after SARS-CoV-2 vaccination. 4 cases of Graves' disease (GD), 2 cases of subacute painful thyroiditis (SAT), 1 case of concurrent GD and SAT and 1 case of atypical subacute thyroiditis. Five patients received BNT162b2 mRNA vaccine, 3 patients 1273 mRNA vaccine. The onset of symptoms following vaccination ranged from 10 to 14 days in six of eight patients and from 7 to 8 weeks in two patients.
Several hypotheses have been proposed to explain the potential correlation between SARS-CoV-2 vaccination and thyrotoxicosis, including immune system hyper-stimulation, molecular mimicry and Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA). We should pay greater attention to thyroid disorders in patients receiving vaccine against SARS-CoV-2.
描述一系列可能由 SARS-CoV-2 疫苗接种引发的甲状腺功能亢进病例，并提醒医生注意这种潜在的相关性。报告临床、实验室和影像学发现，并提供进一步与潜在机制相符的信息。
基于医院病历中收集的所有信息以及症状发作与 COVID-19 疫苗接种之间的时间顺序，进行单中心病例系列研究。
我们报告了 8 例 SARS-CoV-2 疫苗接种后发生的甲状腺功能亢进病例。4 例格雷夫斯病（GD），2 例亚急性甲状腺炎（SAT），1 例 GD 和 SAT 同时发生，1 例非典型亚急性甲状腺炎。5 例患者接种了 BNT162b2 mRNA 疫苗，3 例患者接种了 1273 mRNA 疫苗。8 例患者中有 6 例在接种后 10-14 天出现症状，2 例在接种后 7-8 周出现症状。
已经提出了几种假设来解释 SARS-CoV-2 疫苗接种与甲状腺功能亢进之间的潜在相关性，包括免疫系统过度刺激、分子模拟和佐剂诱导的自身免疫/自身炎症综合征（ASIA）。我们应该更加关注接受 SARS-CoV-2 疫苗接种的患者中的甲状腺疾病。
